GenSight Biologics Announces Successful Fundraising Amounting to Nearly €2.9 Million

GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel

GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2 Million

GenSight Biologics Announces Successful Fundraising Amounting to Nearly €2 Million

GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 3.7 Million

GenSight Biologics Announces Successful Fundraising Amounting to Nearly EUR 3.7 Million

GenSight Biologics Reports Cash Position as of June 30, 2025

GenSight Biologics Announces the Closing of the Company’s c. €4 Million Private Placement

GenSight Biologics Announces Successful Completion of a Private Placement of Close to EUR 4 Million

GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France